Pya Y 1
1. Assessing Quality of Life in Hemodialysis Patients in Kazakhstan: A Cross-Sectional Study
2. From Uncertainty to Consent: Educational Intervention Effects on Knowledge and Willingness to Donate Organs After Death
3. Health and Treatment-Related Anxiety among Kidney Transplant Recipients in Kazakhstan
4. The Determinants of Psychological Well-Being Among Kidney Transplant Recipients in Kazakhstan: A Cross-Sectional Study
5. Influence of Genetic Polymorphisms in CYP3A5, CYP3A4, and MDR1 on Tacrolimus Metabolism after kidney transplantation
6. Whole-Exome Sequencing Followed by dPCR-Based Personalized Genetic Approach in Solid Organ Transplantation: A Study Protocol and Preliminary Results
7. Whole-exome sequencing of kidney transplant recipients and donors: insights into end-stage renal disease and post-transplant genetic risk
8. Barriers and willingness to express consent to organ donation among the Kazakhstani population
9. Too uncertain to consent, too supportive to refuse: the sociocultural dilemma of hesitant organ donors in Kazakhstan
10. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): third Paediatric (Paedi-EUROMACS) report
11. The European Registry for Patients with Mechanical Circulatory Support of the European Association for Cardio-Thoracic Surgery: third report
12. Enhanced Donor Lung Viability During Prolonged Ex Vivo Lung Perfusion Using ECMO Technology
13. Trade-Off Between Bleeding and Ischemic Events From Left Ventricular Assist Devices: A EUROMACS Registry Analysis
14. Aspirin and Hemocompatibility after LVAD Implantation in Patients with Atherosclerotic Vascular Disease: A Secondary Analysis from the ARIES-HM3 Randomized Clinical Trial
15. Successful Heart Transplantation After 7 h of Cold Storage and Paracorporeal Donor Heart Resuscitation
16. Hemadsorption in patients requiring V-A ECMO support: Comparison of Cytosorb versus Jafron HA330
17. Impact of concomitant cardiac valvular surgery during implantation of continuous-flow left ventricular assist devices: A European registry for patients with mechanical circulatory support (EUROMACS) analysis
18. Successful heart transplantation after 17 h ex vivo time using the Organ Care System—3 years follow-up
19. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial
20. Case report: Transcatheter tricuspid valve-in-valve implantation using novel balloon-expandable aortic valve with 1 year follow-up
21. The First Pediatric LAMPOON Procedure for TMVR (Valve-in-Ring)
22. First 5-year multicentric clinical trial experience with the HeartMate 3 left ventricular assist system
23. First Clinical Experience With the Pressure Sensor-Based Autoregulation of Blood Flow in an Artificial Heart
24. Preliminary report of extracorporeal blood purification therapy in patients receiving LVAD: Cytosorb or Jafron HA330
25. Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy
26. Bioprosthetic Total Artificial Heart Implantation Does Not Induce Chronic Inflammation
27. Bioprosthetic Total Artificial Heart in Autoregulated Mode Is Biologically Hemocompatible: Insights for Multimers of von Willebrand Factor
28. Progressive endothelial coverage enhances hemocompatibility and prevents calcification in bioprosthetic valve tissue
29. Propensity score-based analysis of long-term follow-up in patients supported with durable centrifugal left ventricular assist devices: The EUROMACS analysis
30. Case report: A novel surgical technique for rapid valve-in-ring implantation into the native aortic annulus during left ventricular assist device implantation
31. Elimination of drive exit line: transcutaneous energy transmission
32. Mortality predictors of hospitalized patients with COVID-19: Retrospective cohort study from Nur-Sultan, Kazakhstan
33. Precise monitoring of transpulmonic resistance in bridge-to-transplant patients supported by the Aeson total artificial heart
34. Response to the manuscript “ex vivo donor heart preservation in heart transplantation (HTx)—Is this the solution to increase the donor pool?”
35. The European Registry for Patients with Mechanical Circulatory Support (EUROMACS): fourth Paediatric EUROMACS (Paedi-EUROMACS) report
36. Attitudes toward posthumous organ donation in Kazakhstan: a qualitative analysis
37. Metabolomics in Search of Noninvasive Biomarkers for Allograft Rejection in Pediatric Kidney Transplantation
38. Five-year outcomes of patients supported with HeartMate 3: A single-centre experience
39. Fully magnetically centrifugal left ventricular assist device and long-term outcomes: the ELEVATE registry
40. Evaluation of liver transplantation services in Kazakhstan from 2012 to 2023
41. Examining a 12-year experience within Kazakhstan’s national heart transplantation program
42. Understanding Pediatric Kidney Transplant Rejection: Its Pathophysiology, Biomarkers, and Management Strategies
43. Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
44. Understanding Platelet Activation in the Aeson Bioprosthetic Total Artificial Heart: Insights From Aspirin Treatment and Outcomes
45. Beyond Survival: A 12-Year Chronicle of Pediatric Kidney Transplantation in Kazakhstan
46. ALCAPA in adult asymptomatic patient: A case report
47. Impact of Atrial Fibrillation, Diabetes Mellitus, and Obesity on Outcomes With Aspirin Avoidance and Hemocompatibility With a Left Ventricular Assist Device: An Analysis From the ARIES-HM3 Trial
48. The fourth report of the European Registry for Patients with Mechanical Circulatory Support (EUROMACS) of the European Association for Cardiothoracic Surgery: focus on standardized outcome ratios
49. Implantation Technique for the Aeson Total Artificial Heart
1